SHR-1701 in Metastatic or Locally Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this Phase I study is to access the safety and tolerability of SHR-1701
at different dose levels. It is hoped to find out the recommended dose for Phase II/III.